Merck Stock: Is $70 Billion Pipeline Enough to Offset Keytruda Decline?

Merck's (MRK) stock has shown impressive long-term strength, but its recent dip raises questions about whether investors are paying too much for the company's future growth. The stock's trend strength places it in the top 6% of US stocks worth more than $1 billion, and a powerful pipeline of new products is fueling this momentum.

The pipeline includes over 20 new products with potential to generate greater than $70 billion in commercial opportunity, including recent FDA approval for LIPFENDRA, an oral cholesterol-lowering drug. However, the company's current financial profile shows room for improvement, with revenue growth lagging behind the S&P 500 median and operating margins below the benchmark.

The stock trades at a premium, with a price-to-earnings multiple of 112.8 far above the S&P 500 median of 22.9. However, removing one-off charges that distorted trailing earnings brings the forward P/E ratio down to roughly 15.2. The challenge lies in transitioning from KEYTRUDA's exclusivity loss in 2028 and ramping up new products quickly enough to offset this decline.

The real test is turning clinical approvals into revenue, with the commercial adoption of newly launched products being a key watchable. Merck's growth will be determined by its ability to execute on its vast portfolio under a ticking clock.